Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10107485 | 0.88 | HDAC9 (0.37) | AKR1C1HDAC9ALDH1A1HSD11B1 | |
| SCHEMBL10107462 | 0.88 | HDAC9 (0.37) | AKR1C1HDAC9ALDH1A1HSD11B1 | |
| SCHEMBL10122504 | 0.88 | HDAC9 (0.37) | AKR1C1HDAC9ALDH1A1HSD11B1 | |
| SCHEMBL10107407 | 0.84 | HDAC9 (0.42) | HDAC9LMNA | |
| SCHEMBL10107437 | 0.82 | HDAC9 (0.40) | HDAC9LMNAHTTHDAC4KDM1A | |
| SCHEMBL10122259 | 0.82 | HDAC9 (0.40) | HDAC9LMNAHTTHDAC4KDM1A | |
| SCHEMBL1753359 | 0.82 | SIGMAR1 (0.42) | ALDH1A1HTT | |
| SCHEMBL10067862 | 0.82 | OPRM1 (0.45) | — | |
| SCHEMBL1754813 | 0.82 | OPRM1 (0.45) | — | |
| SCHEMBL10107568 | 0.82 | OPRM1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158783-B2 | MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-8114880-B2 | Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid MTP inhibiting compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-14 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-31 | — | — | US | disclosed |
| US-4144027-A | SHRINKPROOFING KERATIN-CONTAINING FABRICS BY REACTION WITH A POLYETHER POLYOL AND A DIISOCYANATE | MILLIKEN RESEARCH CORPORATION (US) | 1979-03-13 | — | — | US | disclosed |
| US-4115492-A | SPINNING, COOLING, DRAWING | THE DOW CHEMICAL COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4020230-A | Microporous polyethylene hollow fibers and process of preparing them | THE DOW CHEMICAL COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016291-A1 | MTP INHIBITING TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES | PNLIP, APOB, MTPN | AKR1C1 1536/4885HDAC9 3116/4885ALDH1A1 1724/4885 |
| US-20090325980-A1 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS | PNLIP, APOB, LIPC | AKR1C1 2888/4885HDAC9 2506/4885ALDH1A1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.